BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakahara O, Takamori H, Tanaka H, Sakamoto Y, Ikuta Y, Furuhashi S, Watanabe M, Beppu T, Hirota M, Kanemitsu K, Baba H. Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer. Int J Clin Oncol 2010;15:39-45. [DOI: 10.1007/s10147-009-0008-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Öman M, Wettergren Y, Odin E, Westermark S, Naredi P, Hemmingsson O, Taflin H. Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 2021;88:619-31. [PMID: 34132895 DOI: 10.1007/s00280-021-04318-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Kato H, Naiki-Ito A, Suzuki S, Inaguma S, Komura M, Nakao K, Naiki T, Kachi K, Kato A, Matsuo Y, Takahashi S. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. Carcinogenesis 2021;42:940-50. [PMID: 33640964 DOI: 10.1093/carcin/bgab017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Merloni F, Ranallo N, Scortichini L, Giampieri R, Berardi R. Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase. Cancer Drug Resist 2019;2:787-802. [PMID: 35582578 DOI: 10.20517/cdr.2018.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br J Cancer 2018;118:947-54. [PMID: 29515256 DOI: 10.1038/s41416-018-0004-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
5 Murakawa M, Aoyama T, Miyagi Y, Atsumi Y, Kazama K, Yamaoku K, Kanazawa A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yamamoto N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. Oncol Lett 2017;14:1505-11. [PMID: 28789372 DOI: 10.3892/ol.2017.6295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Flores JP, Diasio RB, Saif MW. Drug metabolism and pancreatic cancer. Ann Gastroenterol 2017;30:54-61. [PMID: 28042238 DOI: 10.20524/aog.2016.0074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas 2016;45:425-33. [PMID: 26495780 DOI: 10.1097/MPA.0000000000000501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
8 Kawabata Y, Nishi T, Kidani A, Tajima Y. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma. Pancreas 2015;44:937-44. [PMID: 25906447 DOI: 10.1097/MPA.0000000000000348] [Reference Citation Analysis]
9 Guo YM, Zhu M, Yu WW. Prognostic significance of thymidylate synthase expression in pancreatic adenocarcinoma: A meta-analysis. Mol Clin Oncol 2015;3:121-4. [PMID: 25469281 DOI: 10.3892/mco.2014.443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch HA; PanScan Consortium. Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas 2011;40:657-63. [PMID: 21487324 DOI: 10.1097/MPA.0b013e31821268d1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
11 Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251-265. [PMID: 21332317 DOI: 10.2217/pgs.10.167] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]